UY37497A - Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida - Google Patents
Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamidaInfo
- Publication number
- UY37497A UY37497A UY0001037497A UY37497A UY37497A UY 37497 A UY37497 A UY 37497A UY 0001037497 A UY0001037497 A UY 0001037497A UY 37497 A UY37497 A UY 37497A UY 37497 A UY37497 A UY 37497A
- Authority
- UY
- Uruguay
- Prior art keywords
- methyl
- pyridinyl
- acetamide
- phenyl
- thiazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención refiere a formulaciones farmacéuticas de agentes antivirales activos para aplicación tópica, particularmente para uso en tratamiento de infecciones por virus herpes humano, donde los agentes antivirales activos pueden seleccionarse del grupo comprendiendo: hemihidrato de la base libre de N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)-fenil]-acetamida, la sal maleato de N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamida, la sal de mesilato de N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2- piridinil)fenil]acetamida, y la base libre de N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2- piridinil)fenil]acetamida. Específicamente, se proporcionan dichas formulaciones farmacéuticas comprendiendo un agente antiviral como se ha descrito anteriormente disuelto o solubilizado, hidroxil tolueno butilado (BHT) y PEG 400 Super RefinedTM a un pH aparente de 4,0 a 5,0, preferiblemente a un pH aparente de 4,0 a 4,5.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16201005 | 2016-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY37497A true UY37497A (es) | 2018-06-29 |
Family
ID=57406185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001037497A UY37497A (es) | 2016-11-28 | 2017-11-28 | Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR110250A1 (es) |
TW (1) | TW201825095A (es) |
UY (1) | UY37497A (es) |
WO (1) | WO2018095576A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3692039T1 (sl) | 2017-10-05 | 2023-04-28 | Innovative Molecules Gmbh | Enantomeri substituiranih tiazolov kot protivirusne spojine |
TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
EP3925595A1 (en) * | 2020-06-17 | 2021-12-22 | AiCuris GmbH & Co. KG | Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate |
KR20220160024A (ko) | 2020-03-26 | 2022-12-05 | 아이쿠리스 게엠베하 운트 코. 카게 | N-[5-(아미노술포닐)-4-메틸-1,3-티아졸-2-일]-n-메틸-2-[4-(2-피리디닐)페닐]아세트아미드 반수화물을 포함하는 안과용 제제 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DOP2000000109A (es) | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
DE10129714A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Topische Anwendung von Thiazolylamiden |
DE10129716A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
DE102005014248A1 (de) | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
DK2563374T3 (da) * | 2010-07-08 | 2014-01-20 | Devirex Ag | Polyethylenglycolsammensætninger til kontrol af tilbagefald af herpes labialis, herpes genitalis og herpes zoster |
EP2573086A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
-
2017
- 2017-11-28 WO PCT/EP2017/001397 patent/WO2018095576A1/en active Application Filing
- 2017-11-28 TW TW106141481A patent/TW201825095A/zh unknown
- 2017-11-28 UY UY0001037497A patent/UY37497A/es not_active Application Discontinuation
- 2017-11-28 AR ARP170103303A patent/AR110250A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018095576A1 (en) | 2018-05-31 |
TW201825095A (zh) | 2018-07-16 |
AR110250A1 (es) | 2019-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY37497A (es) | Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida | |
CL2018003291A1 (es) | Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018). | |
UY37496A (es) | Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo | |
CR20170411A (es) | Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina | |
EA201792559A1 (ru) | Фармацевтические композиции для местного применения | |
NI201700011A (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
BR112013006953A2 (pt) | composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença | |
MX2019007587A (es) | Composicion oftalmica para el tratamiento de la enfermedad del ojo seco. | |
WO2016042163A3 (en) | Ophthalmic drug compositions | |
CU23423B7 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea | |
AR055363A1 (es) | Formulaciones farmaceuticas que comprenden un beta 2- agonista de accion prolongada para administracion por nebulizacion | |
CL2018000033A1 (es) | Composición para destapar una nariz tapada que tiene actividad antiviral. | |
BRPI0822162B8 (pt) | composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal | |
EA201991299A1 (ru) | Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов | |
BR112021002069A2 (pt) | Composição para tratamento capilar, métodos e usos da mesma. | |
BR112014017780A8 (pt) | Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos | |
MA56547A (fr) | Formulations d'agents pénétrants transdermiques contenant du cannabidiol | |
RU2014139825A (ru) | Производные ингенола для реактивации латентного вируса вич | |
BR112017022521A2 (pt) | agente para controlar doenças em plantas de cereais, método para controlar doenças em plantas de cereais, uso de fluoroimida ou um sal agroquimicamente aceitável da mesma, uso de um ou mais compostos, e uso de fluoroimida ou um sal agroquimicamente aceitável da mesma | |
PE20181522A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
MX2023006235A (es) | Composiciones para administracion de farmacos y metodos de uso de las mismas. | |
AR086491A1 (es) | Composicion farmaceutica que comprende fexofenadina | |
MA40847A (fr) | Association comprenant de la spiruline et du palmitoyléthanolamide et/ou des sels ou des dérivés pharmaceutiquement acceptables de ceux-ci et leurs formulations, pour une utilisation dans la prévention et/ou le traitement d'états d'hyperactivité des tissus | |
JP2016511246A5 (es) | ||
BR112012016549A2 (pt) | piperazinas como agentes antimalariais |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20230705 |